Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes.
Aged
Aged, 80 and over
Angiotensin Receptor Antagonists
/ administration & dosage
COVID-19
/ complications
Dyspnea
/ etiology
Female
Fever
/ etiology
Heparin, Low-Molecular-Weight
/ therapeutic use
Humans
Male
Mental Disorders
/ complications
Neoplasms
/ complications
Nursing Homes
Proportional Hazards Models
Retrospective Studies
Risk Factors
SARS-CoV-2
/ isolation & purification
Sex Factors
Survival Rate
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
11
2020
accepted:
17
02
2021
entrez:
16
3
2021
pubmed:
17
3
2021
medline:
26
3
2021
Statut:
epublish
Résumé
Since the start of the pandemic, millions of people have been infected, with thousands of deaths. Many foci worldwide have been identified in retirement nursing homes, with a high number of deaths. Our study aims were to evaluate the spread of SARS-CoV-2 in the retirement nursing homes, the predictors to develop symptoms, and death. We conducted a retrospective study enrolling all people living in retirement nursing homes (PLRNH), where at least one SARS-CoV-2 infected person was present. Medical and clinical data were collected. Variables were compared with Student's t-test or Pearson chi-square test as appropriate. Uni- and multivariate analyses were conducted to evaluate variables' influence on infection and symptoms development. Cox proportional-hazards model was used to evaluate 30 days mortality predictors, considering death as the dependent variable. We enrolled 382 subjects. The mean age was 81.15±10.97 years, and males were 140(36.7%). At the multivariate analysis, mental disorders, malignancies, and angiotensin II receptor blockers were predictors of SARS-CoV-2 infection while having a neurological syndrome was associated with a lower risk. Only half of the people with SARS-CoV-2 infection developed symptoms. Chronic obstructive pulmonary disease and neurological syndrome were correlated with an increased risk of developing SARS-CoV-2 related symptoms. Fifty-six (21.2%) people with SARS-CoV-2 infection died; of these, 53 died in the first 30 days after the swab's positivity. Significant factors associated with 30-days mortality were male gender, hypokinetic disease, and the presence of fever and dyspnea. Patients' autonomy and early heparin treatment were related to lower mortality risk. We evidenced factors associated with infection's risk and death in a setting with high mortality such as retirement nursing homes, that should be carefully considered in the management of PLRNH.
Identifiants
pubmed: 33724987
doi: 10.1371/journal.pone.0248009
pii: PONE-D-20-34816
pmc: PMC7963051
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Heparin, Low-Molecular-Weight
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248009Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Eur J Intern Med. 2020 Dec;82:38-47
pubmed: 32859477
Environ Pollut. 2020 Nov;266(Pt 1):115161
pubmed: 32645554
Head Neck. 2020 Jun;42(6):1252-1258
pubmed: 32342566
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Mar 28;395(10229):1015-1018
pubmed: 32197103
Geriatr Gerontol Int. 2020 Jul;20(7):704-708
pubmed: 32516861
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Percept Mot Skills. 2003 Dec;97(3 Pt 1):805-10
pubmed: 14738345
Drugs Ther Perspect. 2020 Jun 9;:1-4
pubmed: 32837189
JAMA. 2020 Apr 14;323(14):1343-1344
pubmed: 32125355
Clin Infect Dis. 2020 Jul 20;:
pubmed: 32687150
J Nutr Health Aging. 2020;24(6):560-562
pubmed: 32510106
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Blood Transfus. 2020 May;18(3):167-169
pubmed: 32281926
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e449-e450
pubmed: 32441830
Monaldi Arch Chest Dis. 2020 Jun 10;90(2):
pubmed: 32527073
J Thromb Thrombolysis. 2021 Jan;51(1):226-231
pubmed: 32632558
Int J Infect Dis. 2020 Sep;98:216-217
pubmed: 32623080
JAMA. 2020 Jul 14;324(2):168-177
pubmed: 32558877
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):523-526
pubmed: 33506944
JAMA Cardiol. 2020 Jul 1;5(7):825-830
pubmed: 32324209
Int J Infect Dis. 2020 Oct;99:75-76
pubmed: 32738491
Arch Gerontol Geriatr. 2020 Jul - Aug;89:104058
pubmed: 32339960
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
Head Neck. 2020 Jul;42(7):1560-1569
pubmed: 32437022
Clin Microbiol Infect. 2021 Jan;27(1):19-27
pubmed: 32860962
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7861-7868
pubmed: 32744714
New Microbes New Infect. 2020 Jun 06;38:100709
pubmed: 33088574
Neuropsychiatr Dis Treat. 2020 May 28;16:1359-1367
pubmed: 32547039
JACC Case Rep. 2020 Jul 15;2(9):1407-1410
pubmed: 32373791
PLoS One. 2020 Jul 2;15(7):e0235590
pubmed: 32614889
BMJ. 2020 Feb 28;368:m810
pubmed: 32111649
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
J Med Virol. 2021 Feb;93(2):820-830
pubmed: 32691881
Eur J Clin Invest. 2021 Jan;51(1):e13427
pubmed: 33043447
Mov Disord. 2020 May;35(5):709-710
pubmed: 32250468
Blood Purif. 2021;50(1):28-34
pubmed: 32615569
J Am Med Dir Assoc. 2020 Jul;21(7):915-918
pubmed: 32674819
J Infect. 2020 Jun;80(6):e14-e18
pubmed: 32171866
J Neurol. 2021 Feb;268(2):409-419
pubmed: 32696341
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936776
pubmed: 32687449
Gerontology. 2020;66(5):467-475
pubmed: 32474561
Thromb Haemost. 2017 Feb 28;117(3):437-444
pubmed: 27975101
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088